lung disease

The company said that 20 medical centers in the US are now offering the Envisia Genomic Classifier through an early-access program begun in May.

ProAxsis and a US-based biotechnology company codeveloped the assay as part of an ongoing collaboration. ProAxsis has made its first commercial sale of the test.

Investigators concluded that wearables show early promise in some cases, but there's limited evidence to substantiate claims of their ability to improve outcomes.